Based on the Evotec SE ADR stock forecast from 2 analysts, the average analyst target price for Evotec SE ADR is USD 7.60 over the next 12 months. Evotec SE ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Evotec SE ADR is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Evotec SE ADR’s stock price was USD 4.40. Evotec SE ADR’s stock price has changed by +13.99% over the past week, +28.28% over the past month and -53.19% over the last year.
No recent analyst target price found for Evotec SE ADR
No recent average analyst rating found for Evotec SE ADR
Company Overview Evotec SE ADR
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Read Less
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunol...Read More
Frequently Asked Questions About Evotec SE ADR (EVO) Stock
Based on ratings from 2 analysts Evotec SE ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on EVO's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for EVO is USD 7.60 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 3.8.
EVO stock's Price/Earning ratio is 485.75.
Our analysis grades EVO stock's Price / Earning ratio at F. This means that EVO stock's Price/Earning ratio is above 98% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this EVO may be a overvalued for its sector.
The last closing price of EVO's stock was USD 4.40.
The most recent market capitalization for EVO is USD 1.38B.
Based on targets from 2 analysts, the average taret price for EVO is projected at USD 7.60 over the next 12 months.
This means that EVO's stock price may go up by +72.73% over the next 12 months.
We can't find any ETFs which contains Evotec SE ADR's stock.
As per our most recent records Evotec SE ADR has 5,022 Employees.
Evotec SE ADR's registered address is Essener Bogen 7, Hamburg, Germany, 22419.
You can get more information about it from Evotec SE ADR's website at https://www.evotec.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Evotec SE ADR (EVO) Stock
Based on ratings from 2 analysts Evotec SE ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on EVO's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for EVO is USD 7.60 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 3.8.
EVO stock's Price/Earning ratio is 485.75.
Our analysis grades EVO stock's Price / Earning ratio at F. This means that EVO stock's Price/Earning ratio is above 98% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this EVO may be a overvalued for its sector.
The last closing price of EVO's stock was USD 4.40.
The most recent market capitalization for EVO is USD 1.38B.
Based on targets from 2 analysts, the average taret price for EVO is projected at USD 7.60 over the next 12 months.
This means that EVO's stock price may go up by +72.73% over the next 12 months.
We can't find any ETFs which contains Evotec SE ADR's stock.
As per our most recent records Evotec SE ADR has 5,022 Employees.
Evotec SE ADR's registered address is Essener Bogen 7, Hamburg, Germany, 22419.
You can get more information about it from Evotec SE ADR's website at https://www.evotec.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EVO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
